Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics Inc (NQ: VTGN )

3.110 +0.030 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Top Investor Conferences
Via Investor Brand Network
VistaGen to Participate in Upcoming June Investor Conferences
From VistaGen Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
On Monday, 149 companies reached new 52-week lows. 
Via Benzinga
Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
Deals, financings, trials and approvals in biotech in China this week. 
Via Talk Markets
Recap: VistaGen Therapeutics Q3 Earnings
VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows. 
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
VistaGen Appoints Reid Adler as Chief Legal Officer
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses
Via Investor Brand Network
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
Via Investor Brand Network
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to... 
Via Benzinga
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54... 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update
Via Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call
Via Investor Brand Network
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18
Via Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights
Via Investor Brand Network
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update
Via Investor Brand Network
VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers MorphoSys (NASDAQ:MOR) stock move... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.